Klaus Breiner

Klaus Breiner is a venture capital investor since 2001, joined Bellevue in 2004. Co-founder and former Executive Chairman of Vaximm, a Swiss-German immuno-oncology company. Prior to Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Cadence, Glycart, Intercell, Vaximm and AM-Pharma. PhD Molecular Biologist & Chemist.